Intelligence Profile
Research Papers
Research Papers and Clinical Trials
The research on bremelanotide (PT-141) includes several completed clinical trials and ongoing academic research, though detailed study results are limited in the available evidence.
Clinical Trials
Two major Phase 3 clinical trials (NCT02338960 and NCT02333071) have been completed evaluating bremelanotide's efficacy and safety in premenopausal women with hypoactive sexual desire disorder (HSDD). An earlier Phase 2 trial (NCT01382719) examined the drug's effects in premenopausal women with both female sexual arousal disorder and HSDD. While these trials are marked as completed, specific results, sample sizes, and detailed outcomes are not provided in the available evidence.
Academic Research
Recent academic literature suggests continued interest in bremelanotide's therapeutic applications. A 2026 systematic review examined clinical trial evidence for emerging pharmacological therapies for HSDD in women, likely including bremelanotide among the treatments analyzed. Another 2026 paper specifically questioned whether bremelanotide should be considered for treating sexual arousal and desire disorders in men, suggesting research interest beyond its current approved indication.
Additional research has explored bremelanotide in specialized contexts, including strategies for treating sexual health concerns after breast and gynecologic cancer, and practical approaches for managing sexual symptoms in breast cancer patients on endocrine therapies.
Research Gaps
The available evidence shows that while clinical trials have been completed and academic interest continues, detailed study methodologies, sample sizes, and specific clinical outcomes are not readily accessible in the current literature summaries. More comprehensive data from the completed trials would be needed to fully assess the clinical evidence base.
Note: This synthesis is based on limited available evidence. Consult healthcare providers for current clinical recommendations and detailed study results.